Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 127 entries
Sorted by: Best Match Show Resources per page
Simplified Warfarin Dose-response Pharmacodynamic Models.

Biomedical engineering : applications, basis, and communications

Kim S, Gaweda AE, Wu D, Li L, Rai SN, Brier ME.
PMID: 25750489
Biomed Eng (Singapore). 2015 Feb;27(1). doi: 10.4015/S1016237215500015.

Warfarin is a frequently used oral anticoagulant for long-term prevention and treatment of thromboembolic events. Due to its narrow therapeutic range and large inter-individual dose-response variability, it is highly desirable to personalize warfarin dosing. However, the complexity of the...

Cite
Kim S, Gaweda AE, Wu D, et al. Simplified Warfarin Dose-response Pharmacodynamic Models. Biomed Eng (Singapore). 2015;27(1)doi: 10.4015/S1016237215500015.
Kim, S., Gaweda, A. E., Wu, D., Li, L., Rai, S. N., & Brier, M. E. (2015). Simplified Warfarin Dose-response Pharmacodynamic Models. Biomedical engineering : applications, basis, and communications, 27(1), . https://doi.org/10.4015/S1016237215500015
Kim, Seongho, et al. "Simplified Warfarin Dose-response Pharmacodynamic Models." Biomedical engineering : applications, basis, and communications vol. 27,1 (2015). doi: https://doi.org/10.4015/S1016237215500015
Kim S, Gaweda AE, Wu D, Li L, Rai SN, Brier ME. Simplified Warfarin Dose-response Pharmacodynamic Models. Biomed Eng (Singapore). 2015 Feb;27(1). doi: 10.4015/S1016237215500015. PMID: 25750489; PMCID: PMC4349334.
Copy Download .nbib Format: NLM
Development of cabozantinib for the treatment of prostate cancer.

Core evidence

Vaishampayan UN.
PMID: 24790591
Core Evid. 2014 Apr 23;9:61-7. doi: 10.2147/CE.S48498. eCollection 2014.

Cabozantinib (XL184) is a multitargeted receptor tyrosine kinase with predominantly MET and vascular endothelial growth factor inhibition properties. It is currently approved by the US Food and Drug Administration for the treatment of progressive metastatic medullary thyroid cancer. The...

Cite
Vaishampayan UN. Development of cabozantinib for the treatment of prostate cancer. Core Evid. 2014;9:61-7doi: 10.2147/CE.S48498.
Vaishampayan, U. N. (2014). Development of cabozantinib for the treatment of prostate cancer. Core evidence, 961-7. https://doi.org/10.2147/CE.S48498
Vaishampayan, Ulka N. "Development of cabozantinib for the treatment of prostate cancer." Core evidence vol. 9 (2014): 61-7. doi: https://doi.org/10.2147/CE.S48498
Vaishampayan UN. Development of cabozantinib for the treatment of prostate cancer. Core Evid. 2014 Apr 23;9:61-7. doi: 10.2147/CE.S48498. eCollection 2014. PMID: 24790591; PMCID: PMC4003147.
Copy Download .nbib Format: NLM
Tracking and treating activated T cells.

Journal of drug delivery science and technology

Kim NH, Nadithe V, Elsayed M, Merkel OM.
PMID: 24660025
J Drug Deliv Sci Technol. 2013 Jan 01;23(1):17-21. doi: 10.1016/s1773-2247(13)50002-5.

Upon activation, T cells of various subsets are the most important mediators in cell-mediated immune responses. Activated T cells play an important role in immune system related diseases such as chronic inflammatory diseases, viral infections, autoimmune disease, transplant rejection,...

Cite
Kim NH, Nadithe V, Elsayed M, et al. Tracking and treating activated T cells. J Drug Deliv Sci Technol. 2013;23(1):17-21doi: 10.1016/s1773-2247(13)50002-5.
Kim, N. H., Nadithe, V., Elsayed, M., & Merkel, O. M. (2013). Tracking and treating activated T cells. Journal of drug delivery science and technology, 23(1), 17-21. https://doi.org/10.1016/s1773-2247(13)50002-5
Kim, N H, et al. "Tracking and treating activated T cells." Journal of drug delivery science and technology vol. 23,1 (2013): 17-21. doi: https://doi.org/10.1016/s1773-2247(13)50002-5
Kim NH, Nadithe V, Elsayed M, Merkel OM. Tracking and treating activated T cells. J Drug Deliv Sci Technol. 2013 Jan 01;23(1):17-21. doi: 10.1016/s1773-2247(13)50002-5. PMID: 24660025; PMCID: PMC3959737.
Copy Download .nbib Format: NLM
Peroxisomes, oxidative stress, and inflammation.

World journal of biological chemistry

Terlecky SR, Terlecky LJ, Giordano CR.
PMID: 22649571
World J Biol Chem. 2012 May 26;3(5):93-7. doi: 10.4331/wjbc.v3.i5.93.

Peroxisomes are intracellular organelles mediating a wide variety of biosynthetic and biodegradative reactions. Included among these are the metabolism of hydrogen peroxide and other reactive species, molecules whose levels help define the oxidative state of cells. Loss of oxidative...

Cite
Terlecky SR, Terlecky LJ, Giordano CR. Peroxisomes, oxidative stress, and inflammation. World J Biol Chem. 2012;3(5):93-7doi: 10.4331/wjbc.v3.i5.93.
Terlecky, S. R., Terlecky, L. J., & Giordano, C. R. (2012). Peroxisomes, oxidative stress, and inflammation. World journal of biological chemistry, 3(5), 93-7. https://doi.org/10.4331/wjbc.v3.i5.93
Terlecky, Stanley R, et al. "Peroxisomes, oxidative stress, and inflammation." World journal of biological chemistry vol. 3,5 (2012): 93-7. doi: https://doi.org/10.4331/wjbc.v3.i5.93
Terlecky SR, Terlecky LJ, Giordano CR. Peroxisomes, oxidative stress, and inflammation. World J Biol Chem. 2012 May 26;3(5):93-7. doi: 10.4331/wjbc.v3.i5.93. PMID: 22649571; PMCID: PMC3362841.
Copy Download .nbib Format: NLM
The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

American journal of cancer research

Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH.
PMID: 30416858
Am J Cancer Res. 2018 Oct 01;8(10):2088-2095. eCollection 2018.

MicroRNAs (miRNAs) constitute short non-coding RNAs that can post-transcriptionally modulate the expression of many oncogenes and tumor suppressor genes engaged in key cellular processes. Deregulated serum miRNA signatures have been detected in various solid cancers including prostate cancer, suggesting...

Cite
Dyson G, Farran B, Bolton S, et al. The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res. 2018;8(10):2088-2095
Dyson, G., Farran, B., Bolton, S., Craig, D. B., Dombkowski, A., Beebe-Dimmer, J. L., Powell, I. J., Podgorski, I., Heilbrun, L. K., & Bock, C. H. (2018). The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. American journal of cancer research, 8(10), 2088-2095.
Dyson, Greg, et al. "The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer." American journal of cancer research vol. 8,10 (2018): 2088-2095.
Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH. The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res. 2018 Oct 01;8(10):2088-2095. eCollection 2018. PMID: 30416858; PMCID: PMC6220145.
Copy Download .nbib Format: NLM
A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.

Oncotarget

Cheriyan VT, Alsaab HO, Sekhar S, Stieber C, Kesharwani P, Sau S, Muthu M, Polin LA, Levi E, Iyer AK, Rishi AK.
PMID: 29285223
Oncotarget. 2017 Sep 05;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 01.

Current treatments for Renal Cell Carcinoma (RCC) include a combination of surgery, targeted therapy, and immunotherapy. Emergence of resistant RCCs contributes to failure of drugs and poor prognosis, and thus warrants development of new and improved treatment options for...

Cite
Cheriyan VT, Alsaab HO, Sekhar S, et al. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma. Oncotarget. 2017;8(62):104928-104945doi: 10.18632/oncotarget.20650.
Cheriyan, V. T., Alsaab, H. O., Sekhar, S., Stieber, C., Kesharwani, P., Sau, S., Muthu, M., Polin, L. A., Levi, E., Iyer, A. K., & Rishi, A. K. (2017). A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma. Oncotarget, 8(62), 104928-104945. https://doi.org/10.18632/oncotarget.20650
Cheriyan, Vino T, et al. "A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma." Oncotarget vol. 8,62 (2017): 104928-104945. doi: https://doi.org/10.18632/oncotarget.20650
Cheriyan VT, Alsaab HO, Sekhar S, Stieber C, Kesharwani P, Sau S, Muthu M, Polin LA, Levi E, Iyer AK, Rishi AK. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma. Oncotarget. 2017 Sep 05;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 01. PMID: 29285223; PMCID: PMC5739610.
Copy Download .nbib Format: NLM
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.
PMID: 28721379
NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute...

Cite
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017doi: 10.1038/npjbcancer.2016.17.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 216017. https://doi.org/10.1038/npjbcancer.2016.17
Petkov, Valentina I, et al. "Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 2 (2016): 16017. doi: https://doi.org/10.1038/npjbcancer.2016.17
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016. PMID: 28721379; PMCID: PMC5515329.
Copy Download .nbib Format: NLM
Cell-free DNA results lead to unexpected diagnosis.

Clinical case reports

Smith J, Kean V, Bianchi DW, Feldman G, Petrucelli N, Simon M, Gonik B.
PMID: 28781851
Clin Case Rep. 2017 Jul 03;5(8):1323-1326. doi: 10.1002/ccr3.1051. eCollection 2017 Aug.

Maternal cell-free DNA (cfDNA) results that are discordant with the diagnostic fetal karyotype should prompt further investigation. If deeper analysis of the cfDNA results demonstrates a "saw-tooth" pattern characteristic of genome-wide imbalance, maternal malignancy is suggested. Identifying the maternal...

Cite
Smith J, Kean V, Bianchi DW, et al. Cell-free DNA results lead to unexpected diagnosis. Clin Case Rep. 2017;5(8):1323-1326doi: 10.1002/ccr3.1051.
Smith, J., Kean, V., Bianchi, D. W., Feldman, G., Petrucelli, N., Simon, M., & Gonik, B. (2017). Cell-free DNA results lead to unexpected diagnosis. Clinical case reports, 5(8), 1323-1326. https://doi.org/10.1002/ccr3.1051
Smith, Jessica, et al. "Cell-free DNA results lead to unexpected diagnosis." Clinical case reports vol. 5,8 (2017): 1323-1326. doi: https://doi.org/10.1002/ccr3.1051
Smith J, Kean V, Bianchi DW, Feldman G, Petrucelli N, Simon M, Gonik B. Cell-free DNA results lead to unexpected diagnosis. Clin Case Rep. 2017 Jul 03;5(8):1323-1326. doi: 10.1002/ccr3.1051. eCollection 2017 Aug. PMID: 28781851; PMCID: PMC5538058.
Copy Download .nbib Format: NLM
Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury.

Frontiers in genetics

Sen A, Gurdziel K, Liu J, Qu W, Nuga OO, Burl RB, Hüttemann M, Pique-Regi R, Ruden DM.
PMID: 29187863
Front Genet. 2017 Nov 15;8:175. doi: 10.3389/fgene.2017.00175. eCollection 2017.

Traumatic brain injury (TBI) can cause persistent pathological alteration of neurons. This may lead to cognitive dysfunction, depression and increased susceptibility to life threatening diseases, such as epilepsy and Alzheimer's disease. To investigate the underlying genetic and molecular basis...

Cite
Sen A, Gurdziel K, Liu J, et al. Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury. Front Genet. 2017;8:175doi: 10.3389/fgene.2017.00175.
Sen, A., Gurdziel, K., Liu, J., Qu, W., Nuga, O. O., Burl, R. B., Hüttemann, M., Pique-Regi, R., & Ruden, D. M. (2017). Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury. Frontiers in genetics, 8175. https://doi.org/10.3389/fgene.2017.00175
Sen, Arko, et al. "Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury." Frontiers in genetics vol. 8 (2017): 175. doi: https://doi.org/10.3389/fgene.2017.00175
Sen A, Gurdziel K, Liu J, Qu W, Nuga OO, Burl RB, Hüttemann M, Pique-Regi R, Ruden DM. Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury. Front Genet. 2017 Nov 15;8:175. doi: 10.3389/fgene.2017.00175. eCollection 2017. PMID: 29187863; PMCID: PMC5694756.
Copy Download .nbib Format: NLM
Parametric Linkage Analysis Identifies Five Novel Genome-Wide Significant Loci for Familial Lung Cancer.

Human heredity

Musolf AM, Simpson CL, de Andrade M, Mandal D, Gaba C, Yang P, Li Y, You M, Kupert EY, Anderson MW, Schwartz AG, Pinney SM, Amos CI, Bailey-Wilson JE.
PMID: 28817824
Hum Hered. 2016;82(1):64-74. doi: 10.1159/000479028. Epub 2017 Aug 18.

OBJECTIVE: One of four American cancer patients dies of lung cancer. Environmental factors such as tobacco smoking are known to affect lung cancer risk. However, there is a genetic factor to lung cancer risk as well. Here, we perform...

Cite
Musolf AM, Simpson CL, de Andrade M, et al. Parametric Linkage Analysis Identifies Five Novel Genome-Wide Significant Loci for Familial Lung Cancer. Hum Hered. 2017;82(1):64-74doi: 10.1159/000479028.
Musolf, A. M., Simpson, C. L., de Andrade, M., Mandal, D., Gaba, C., Yang, P., Li, Y., You, M., Kupert, E. Y., Anderson, M. W., Schwartz, A. G., Pinney, S. M., Amos, C. I., & Bailey-Wilson, J. E. (2016). Parametric Linkage Analysis Identifies Five Novel Genome-Wide Significant Loci for Familial Lung Cancer. Human heredity, 82(1), 64-74. https://doi.org/10.1159/000479028
Musolf, Anthony M, et al. "Parametric Linkage Analysis Identifies Five Novel Genome-Wide Significant Loci for Familial Lung Cancer." Human heredity vol. 82,1 (2016): 64-74. doi: https://doi.org/10.1159/000479028
Musolf AM, Simpson CL, de Andrade M, Mandal D, Gaba C, Yang P, Li Y, You M, Kupert EY, Anderson MW, Schwartz AG, Pinney SM, Amos CI, Bailey-Wilson JE. Parametric Linkage Analysis Identifies Five Novel Genome-Wide Significant Loci for Familial Lung Cancer. Hum Hered. 2016;82(1):64-74. doi: 10.1159/000479028. Epub 2017 Aug 18. PMID: 28817824; PMCID: PMC8459795.
Copy Download .nbib Format: NLM
Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy.

Journal of thoracic disease

Watza D, Purrington KS, Chen K, Schwartz AG.
PMID: 29268459
J Thorac Dis. 2017 Nov;9(11):4162-4164. doi: 10.21037/jtd.2017.10.35.

No abstract available.

Cite
Watza D, Purrington KS, Chen K, et al. Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis. 2017;9(11):4162-4164doi: 10.21037/jtd.2017.10.35.
Watza, D., Purrington, K. S., Chen, K., & Schwartz, A. G. (2017). Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. Journal of thoracic disease, 9(11), 4162-4164. https://doi.org/10.21037/jtd.2017.10.35
Watza, Donovan, et al. "Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy." Journal of thoracic disease vol. 9,11 (2017): 4162-4164. doi: https://doi.org/10.21037/jtd.2017.10.35
Watza D, Purrington KS, Chen K, Schwartz AG. Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis. 2017 Nov;9(11):4162-4164. doi: 10.21037/jtd.2017.10.35. PMID: 29268459; PMCID: PMC5721072.
Copy Download .nbib Format: NLM
A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer.

American journal of translational research

Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH.
PMID: 20733950
Am J Transl Res. 2010 Jul 23;2(4):402-11.

UNLABELLED: 3, 3'-diindolylmethane (DIM) modulates estrogen metabolism and acts as an anti-androgen which down-regulates the androgen receptor and prostate specific antigen (PSA). We conducted a dose-escalation, phase I study of BioResponse (BR)-DIM with objectives to determine the maximum tolerated...

Cite
Heath EI, Heilbrun LK, Li J, et al. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res. 2010;2(4):402-11
Heath, E. I., Heilbrun, L. K., Li, J., Vaishampayan, U., Harper, F., Pemberton, P., & Sarkar, F. H. (2010). A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. American journal of translational research, 2(4), 402-11.
Heath, Elisabeth I, et al. "A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer." American journal of translational research vol. 2,4 (2010): 402-11.
Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res. 2010 Jul 23;2(4):402-11. PMID: 20733950; PMCID: PMC2923864.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 127 entries